- Home
- BLRX vs BRTX Comparison
BLRX vs BRTX Comparison
Compare BLRX & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BLRX
- BRTX
- Stock Information
- Founded
- BLRX 2003
- BRTX 1997
- Country
- BLRX Israel
- BRTX United States
- Employees
- BLRX N/A
- BRTX N/A
- Industry
- BLRX Biotechnology: Pharmaceutical Preparations
- BRTX Managed Health Care
- Sector
- BLRX Health Care
- BRTX Health Care
- Exchange
- BLRX Nasdaq
- BRTX Nasdaq
- Market Cap
- BLRX 12.2M
- BRTX 11.2M
- IPO Year
- BLRX 2011
- BRTX N/A
- Fundamental
- Price
- BLRX $3.10
- BRTX $1.85
- Analyst Decision
- BLRX Buy
- BRTX Strong Buy
- Analyst Count
- BLRX 2
- BRTX 1
- Target Price
- BLRX $26.00
- BRTX $18.00
- AVG Volume (30 Days)
- BLRX 26.4K
- BRTX 48.0K
- Earning Date
- BLRX 05-27-2025
- BRTX 03-27-2025
- Dividend Yield
- BLRX N/A
- BRTX N/A
- EPS Growth
- BLRX N/A
- BRTX N/A
- EPS
- BLRX N/A
- BRTX N/A
- Revenue
- BLRX $28,940,000.00
- BRTX $401,000.00
- Revenue This Year
- BLRX N/A
- BRTX $482.76
- Revenue Next Year
- BLRX N/A
- BRTX $212.24
- P/E Ratio
- BLRX N/A
- BRTX N/A
- Revenue Growth
- BLRX 502.92
- BRTX 175.03
- 52 Week Low
- BLRX $2.85
- BRTX $1.03
- 52 Week High
- BLRX $35.60
- BRTX $2.55
- Technical
- Relative Strength Index (RSI)
- BLRX 41.70
- BRTX 53.36
- Support Level
- BLRX $3.01
- BRTX $1.72
- Resistance Level
- BLRX $3.61
- BRTX $1.85
- Average True Range (ATR)
- BLRX 0.22
- BRTX 0.13
- MACD
- BLRX 0.02
- BRTX 0.02
- Stochastic Oscillator
- BLRX 32.89
- BRTX 50.98
About BLRX BioLineRx Ltd.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
About BRTX BioRestorative Therapies Inc. (NV)
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.